Sanofi S.A. EO-Medium-Term Nts 2026(26/29)
- BID
99.532
- ASK
99.67
- 500,000 Nom.500,000 Nom.
- 07/27, 19:06:35 PM
Type of financial instrument
Corporate Bond
Sub-Type
Health Care
Yield
3.18
Yield spread Bundesanleihe
0.3894
Tradable for private investors
No
Minimum amount tradeable unit
100,000.00
Maturity
05/05/2029
Interest Rate
3.00 %
Currency
Euro
Facts & figures
Price data
| TRADE PLATFORM | Börse Stuttgart (XSTU) | |
| LAST PRICE / YIELD | 99.532 G / 3.18 | 0 Units |
| PRICE DETERMINATION TIME | 07/27/2026 / 07:06:35 PM | |
| DAILY VOLUME (NOMINAL) | 0 | |
| YIELD SPREAD | 0.3894 | |
| FIXINGPRICE | - | |
| DAILY HIGH / LOW | 99.556 | 99.43 |
| PREV. DAY'S PRICE | 99.419 | (07/24) |
| CHANGE DAY BEFORE | +0.11 | 0.11 % |
| 52 WEEK HIGH / LOW | (-) | (-) |
Master Data
| WKN | A4ET7N |
| ISIN | FR0014016SU0 |
| SYMBOL | - |
| EXCHANGE SEGMENT | Freiverkehr |
| TYPE OF FINANCIAL INSTRUMENT | Corporate Bond |
| SUB-TYPE | Health Care |
| ISSUER | Sanofi S.A. |
| S&P RATING | Please log in to view this field |
| (TRADING) SEGMENT / TICKS | -/ - |
| TRADING HOURS | 07:30:00 AM - 10:00:00 PM |
| INTEREST RATE | 3.00 % |
| INTEREST RUN FROM | 05/05/2026 |
| NEXT INTEREST PAYMENT | 05/05/2027 |
| UNIT INTEREST FROM NOMINAL AMMOUNT | 0.699 % |
| TRADING CURRENCY / NOTATION | Euro/ Percent |
| NOMINAL CURRENCY | Euro |
| SETTLEMENT CURRENCY | Euro |
| QUOTATION | Continuous trading |
| ISSUING VOLUME | 0 |
| MINIMUM AMOUNT TRADEABLE UNIT | 100,000.00 |
| SMALLEST TRADEABLE UNIT | 100,000.00 |
| MATURITY | 05/05/2029 |
| MARKET MAKER | - |
| STEP UP/ DOWN WHEN RATING CHANGES | No |
| STEP UP FIXED AT ISSUE | No |
| STEP DOWN FIXED AT ISSUE | No |
| BOND CALLABLE BY THE ISSUER | No |
| BOND IS SUBORDINATED | Yes |
Tradability Information
Please log in to see the tradability information for this stock.Not registered yet? Create your free account here.
Company profile
Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.